Detalhe da pesquisa
1.
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
Ann Oncol
; 20(4): 709-14, 2009 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-19150940